Extended endocrine therapy combined with agents, such as cyclin dependent kinase (CDK) inhibitors or mammalian target of rapamycin (mTOR) inhibitors is the most current treatment option for ER+ metastatic cancer [2]. This evidence concerns the gene MTOR and metastatic malignant neoplasm.